Expression of TAP1 and TNF-α in HBV-related hepatocellular carcinoma and its clinical significance
- Author:
- No author available
- Journal Title:
- Chinese Journal of Primary Medicine and Pharmacy
- Issue:
- 5
- DOI:
- 10.3760/cma.j.issn.1008-6706.2012.05.002
- Key Word:
- 乙型肝炎病毒;肝癌;表达;Hepatitis B virus;Hepatocellular carcinoma;Expression
Abstract： Objective To explore the association of expression of transporter associated with antigen processing(TAP1),tumor necrosis factor-alpha(TNF-α)with occurrence and development of HBV-related hepatocellular carcinoma(HCC).Methods The expression of TAP1 and TNF-α in 35 liver carcinoma tissues,and 10 normal liver tissues were detected with immunohistochemical EnVision method,The expression and clinical significance of TAP1,TNF-α in HBV-related HCC were analyzed.Furthermore,the association of respective expression quantity with pathological typing of HCC was analyzed.Results The expression of TAP1,TNF-α was negative in hepatocytes of normal liver tissues.91.4％ of HCC tissues expressed TAP1.There was significantly statistical difference in expression of TAP1 between HCC tissues and the normal hepatic tissues(P ＜ 0.05);60％ of HCC tissues expressed TNF-α.There was statistical difference in expression of TNF-α between HCC and the normal hepatic tissues(P ＜ 0.05),and the positive expression rate of TNF-α in well-differenciated HCC tissues was significantly higher than that in poorly-differenciated ones(P ＜ 0.05).Conclusion TAP1-related MHC-Ⅰ restricted antigen processing pathway was possibly normal in HBV-related HCC.The expression quantity of TNF-α was associated with the occurrence and degree of pathological differentiation of HBV-related HCC.
- [1]王九平,王平忠,李军,等.乙型肝炎病毒adr型C区突变调节人类白细胞抗原-Ⅰ的表达[J].2007,(1).
- [2]陈伟红,丁劲,宫卫东,等.乙型肝炎病毒上调HepG2细胞表面HLA-I表达的机制[J].2004,(1).
- [3]陈伟锋,汪谦,张可飞,等.肿瘤坏死因子-α对肝星状细胞形态及表达结缔组织生长因子的影响[J].2005,(8).
- [4]苏是苍,李承彬,胡勤明.慢性乙肝肝纤维化不同分期TNF-α、NO和内毒素水平变化[J].2006,(3).
- [5]吴孟超.原发性肝癌的诊断及治疗进展[J].2008,(4).
- [6]杨季云,张思仲,郭红,等.肿瘤坏死因子α通过激活NF-κB信号通路加快肝细胞周期进程[J].2007,(6).
- [7]Corrias MV,Pistillo MP,Occhino M,etc.Lack of HLA-class I antigens in human neuroblastoma cells: analysis of its relationship to TAP and tapasin expression.[J].2001,57(2).
- [8]C. Brechot,D. Kremsdorf,P. Soussan,etc.Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC): Molecular mechanisms and novel paradigms[J].2010,58(4).
- [9]Hwang IL,Lee JE,Hahm KB,etc.Association between chronic hepatitis B virus infection and interleukin-10, tumor necrosis factor-alpha gene promoter polymorphisms.[J].2006,21(7).
- [10]Horst D,van-Leeuwen D,Hislop AD,etc.A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates.[J].2007,204(8).
- [11]Kaczmarek M,Sikora J,Kaczmarek E,etc.Analysis of expression of MHC class I molecules and TAP genes in malignant human cell lines.[J].2007,45(3).
- [12]L Burt, Nabors,Esther, Suswam,Yuanyuan, Huang,etc.Tumor necrosis factor alpha induces angiogenic factor up-regulation in malignant glioma cells: a role for RNA stabilization and HuR.[J].2003,63(14).
- [13]Eric W, Hewitt.The MHC class I antigen presentation pathway: strategies for viral immune evasion.[J].2003,110(2).
- [14]Yang T,McNally BA,Ferrone S,etc.A single-nucleotide deletion leads to rapid degradation of TAP-1 mRNA in a melanoma cell line.[J].2003,278(17).
- [15]Barbara, Seliger.Different regulation of MHC class I antigen processing components in human tumors.[J].2008,5(4).
- [16]Tilg H.Cytokines and liver diseases.[J].2001,15(10).
- [17]Cornu TI.,Luder CGK.,Naim H. Niewiesk S.,etc.Measles virus and canine distemper virus target proteins into a TAP-independent MHC class I-restricted antigen-processing pathway[J].2001,82(2).
- [18]Noriyoshi Kuzushita*,Norio Hayashi*,Tatsuya Kanto*,etc.Involvement of transporter associated with antigen processing 2 (TAP2) gene polymorphisms in hepatitis C virus infection[J].1999,116(5).
- [19]J W, Fang,W W, Shen,A, Meager,etc.Activation of the tumor necrosis factor-alpha system in the liver in chronic hepatitis B virus infection.[J].1996,91(4).